Additionally, the molecular mechanisms underlying these systemic conditions often target common pathways, such as those involving vascular endothelial growth factor (VEGF), which plays a pivotal role in developing neovascular complications, particularly in type 2 diabetes mellitus (T2DM) [7]. This evidence concerns the gene VEGFA and diabetes mellitus.